Rafferty Asset Management’s Provention Bio, Inc. Common Stock PRVB Stock Holding History

Rafferty Asset Management’s Portfolio PRVB Stock Details PRVB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-8,995	Closed	-$217K	–	1169
2023 Q1	$217K	Buy	+8,995	New	+$113K	﹤0.01%	1097
2021 Q4	–	Sell	-21,440	Closed	-$137K	–	1346
2021 Q3	$137K	Buy	21,440 +8,625	+67%	+$55.4K	﹤0.01%	1207
2021 Q2	$108K	Buy	+12,815	New	+$103K	﹤0.01%	1246

Other funds holding PRVB

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Rafferty Asset Management's PRVB Position: Q2 2023 in Review

Rafferty Asset Management sold out of Provention Bio, Inc. Common Stock (PRVB) in Q2 2023, closing a stake of 8,995 shares — an estimated $217K sold.

Rafferty Asset Management first reported a position in PRVB in Q2 2021 and held it in 3 quarters. The position peaked at $217K in Q1 2023. 1 fund tracked by Wall St. Rank holds PRVB as of Q2 2023.

Rafferty Asset Management reported no remaining Provention Bio, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Rafferty Asset Management sold 8,995 Provention Bio, Inc. Common Stock shares in Q2 2023, an estimated $217K.
Rafferty Asset Management first reported a position in Provention Bio, Inc. Common Stock in Q2 2021 and held it in 3 quarters.
Rafferty Asset Management's Provention Bio, Inc. Common Stock position peaked at $217K in Q1 2023.
1 fund tracked by Wall St. Rank held Provention Bio, Inc. Common Stock as of Q2 2023.

Based on Rafferty Asset Management's 13F filing for Q2 2023, filed 11 Aug 2023.